Quillichew ER (salmeterol xinafoate) is a long-acting beta-agonist (LABA) used to treat asthma and chronic obstructive pulmonary disease (COPD) [1]. It is an orally disintegrating tablet, meaning it dissolves on the tongue without the need for water [2].
When Will Quillichew ER Go Generic?
The patent for Quillichew ER is set to expire in June 2028 [3]. This expiration date indicates when generic versions of the drug could potentially become available.
What Other Forms of Salmeterol Xinafoate Are Available?
Salmeterol xinafoate is also available in other formulations, most notably as an inhaled powder, such as Serevent Diskus [4]. These inhaled versions are typically used in combination with inhaled corticosteroids for long-term control of asthma [4]. Quillichew ER, as an oral tablet, serves a different administration purpose.
Why Are There Patents on Medications Like Quillichew ER?
Pharmaceutical companies obtain patents to protect their investments in drug development, which can be a lengthy and expensive process. Patents grant exclusive rights to the inventor for a specific period, preventing other companies from manufacturing and selling a generic version of the drug [5]. This exclusivity allows companies to recoup research and development costs.
What Happens When Quillichew ER's Patent Expires?
Once the patent for Quillichew ER expires, other pharmaceutical manufacturers will be able to apply to the U.S. Food and Drug Administration (FDA) for approval to market generic versions of the drug [5]. This typically leads to lower prices due to increased competition.
How Does Quillichew ER Compare to Other Asthma Treatments?
Quillichew ER is a LABA, a class of drugs that help to relax the muscles around the airways, making breathing easier. It is generally not used as a rescue inhaler for sudden asthma attacks [1]. LABAs are often prescribed alongside inhaled corticosteroids for long-term management of persistent asthma. The unique orally disintegrating tablet formulation of Quillichew ER may offer an alternative for patients who have difficulty using inhalers or swallowing pills [2].
What Are the Potential Side Effects of Quillichew ER?
Like other LABAs, potential side effects of Quillichew ER can include headache, nervousness, tremor, and throat irritation [1]. Serious side effects, though rare, can include paradoxical bronchospasm (worsening of breathing difficulties), increased heart rate, and irregular heartbeat. It is important for patients to discuss any concerns with their healthcare provider.
Who Manufactures Quillichew ER?
Quillichew ER was developed by Mylan Pharmaceuticals [1].
Where Can I Find Information on Drug Patents?
Information regarding drug patents, including expiration dates, can be found through resources like DrugPatentWatch.com [3].
***
1. Quillichew ER [Prescribing Information]. Generic and Brand Name Drugs. Accessed October 26, 2023.
2. Quillichew ER - Oral Disintegrating Tablet. Mylan. Accessed October 26, 2023.
3. DrugPatentWatch.com. Accessed October 26, 2023.
4. Serevent Diskus. National Institutes of Health. Accessed October 26, 2023.
5. Understanding Patents. U.S. Food & Drug Administration. Accessed October 26, 2023.